Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Nashan

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The Journal of Investigative Dermatology|March 1, 1997
A novel dinucleotide mutation in keratin 10 in the annular epidermolytic ichthyosis variant of bullous congenital ichthyosiform erythrodermaG Y Joh, H Traupe, D Metze, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 19, 2011
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology GroupA Pflugfelder, A-K Welter, U Leiter, et al.
The British Journal of Dermatology|April 20, 2012
Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cellsM Felcht, M Heck, C Weiss, et al.
The British Journal of Dermatology|December 16, 2014
Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort studyE Livingstone, T K Eigentler, C Windemuth-Kieselbach, et al.
British Journal of Cancer|April 20, 2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)A Hauschild, C Garbe, W Stolz, et al.
Leukemia|November 23, 2007
Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3N Booken, A Gratchev, J Utikal, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)Katharina C Kähler, S Hüning, D Nashan, et al.
The British Journal of Dermatology|November 18, 2003
Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopyK Hoffmann, T Gambichler, A Rick, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The Journal of Investigative Dermatology|March 1, 1997
A novel dinucleotide mutation in keratin 10 in the annular epidermolytic ichthyosis variant of bullous congenital ichthyosiform erythrodermaG Y Joh, H Traupe, D Metze, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 19, 2011
Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology GroupA Pflugfelder, A-K Welter, U Leiter, et al.
The British Journal of Dermatology|April 20, 2012
Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cellsM Felcht, M Heck, C Weiss, et al.
The British Journal of Dermatology|December 16, 2014
Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort studyE Livingstone, T K Eigentler, C Windemuth-Kieselbach, et al.
British Journal of Cancer|April 20, 2001
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)A Hauschild, C Garbe, W Stolz, et al.
Leukemia|November 23, 2007
Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3N Booken, A Gratchev, J Utikal, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoidN Kramer, G Müller, S Zierold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Journal of Cancer Research and Clinical Oncology|July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)Katharina C Kähler, S Hüning, D Nashan, et al.
The British Journal of Dermatology|November 18, 2003
Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopyK Hoffmann, T Gambichler, A Rick, et al.
Pageof 8